Trodelvy 200mg Injection (Sacituzumab Govitecan) – Complete Product Description

Trodelvy 200mg Injection (Sacituzumab Govitecan) is a prescription targeted cancer medicine containing sacituzumab govitecan, an antibody-drug conjugate (ADC) used in the treatment of certain advanced cancers. The product information provided here lists the manufacturer as Zytotoxisch and the pack size as 1 injection/vial.

Sacituzumab govitecan combines a monoclonal antibody that targets Trop-2 (trophoblast cell-surface antigen 2) with a chemotherapy payload. Trop-2 is expressed on many types of cancer cells. After binding to Trop-2, sacituzumab govitecan is internalized into the cancer cell and releases SN-38, the active metabolite of irinotecan. SN-38 inhibits topoisomerase I, resulting in DNA damage and cancer-cell death.

Trodelvy is primarily used in selected patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and in certain patients with HR-positive, HER2-negative breast cancer, depending on the applicable approved indication and treatment history.

The product listed here is Trodelvy 200mg Injection, with a pack size of 1 injection/vial. It is administered by intravenous infusion under the supervision of a qualified healthcare professional.

Trodelvy 200mg Injection – Product Information

Brand Name: Trodelvy
Active Ingredient: Sacituzumab Govitecan
Strength: 200mg
Dosage Form: Powder for concentrate for solution for intravenous infusion
Route of Administration: Intravenous (IV) infusion
Manufacturer: Zytotoxisch
Pack Size: 1 injection/vial
Drug Class: Antibody-drug conjugate (ADC)
Target: Trop-2
Therapeutic Class: Antineoplastic / Targeted cancer therapy
Prescription Status: Prescription medicine

What Is Trodelvy 200mg Injection Used For?

Trodelvy contains sacituzumab govitecan and is used for selected patients with advanced or metastatic breast cancer.

Depending on the applicable indication and patient’s previous treatment, Trodelvy may be prescribed for:

• Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
• HR-positive, HER2-negative unresectable locally advanced or metastatic breast cancer in selected patients

Treatment eligibility depends on the cancer subtype, disease stage, previous systemic treatments and the prescribing oncologist’s assessment.

Trodelvy for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a breast cancer subtype that does not have significant expression of estrogen receptors, progesterone receptors or HER2.

Because TNBC does not respond to conventional hormone therapies or many HER2-targeted treatments, treatment options can be more limited.

Sacituzumab govitecan provides a targeted antibody-drug conjugate approach by recognizing Trop-2 on cancer cells and delivering the SN-38 payload directly into the tumor environment.

Trodelvy may be used in appropriately selected patients with unresectable locally advanced or metastatic TNBC after previous systemic treatment.

Trodelvy for HR-Positive, HER2-Negative Breast Cancer

Trodelvy is also used in certain patients with hormone receptor-positive (HR-positive), HER2-negative unresectable locally advanced or metastatic breast cancer following appropriate previous therapies.

The exact treatment sequence depends on prior endocrine therapy, chemotherapy, targeted treatment and the patient’s overall clinical condition.

How Does Trodelvy (Sacituzumab Govitecan) Work?

Trodelvy is an antibody-drug conjugate consisting of three important components:

1. Monoclonal antibody: Targets Trop-2 on cancer cells.
2. Linker: Connects the antibody to the chemotherapy payload.
3. SN-38 payload: A potent topoisomerase I inhibitor.

After intravenous administration, the antibody portion binds to Trop-2 on cancer cells.

The complex is then internalized by the cell, where the linker is processed and SN-38 is released.

SN-38 interferes with topoisomerase I, an enzyme required for DNA replication. This causes DNA damage and can result in cancer-cell death.

The drug’s payload can also affect nearby cells, contributing to a bystander effect.

Trodelvy 200mg Dose and Administration

Trodelvy is administered by intravenous infusion.

The commonly recommended adult dose is 10mg/kg, administered on Days 1 and 8 of a 21-day treatment cycle.

Treatment is generally continued until disease progression or unacceptable toxicity, unless the treating oncologist determines otherwise.

The 200mg vial is a presentation strength and does not necessarily represent the complete dose for one infusion. The number of vials required is calculated according to the patient’s body weight.

Trodelvy should be prepared and administered by qualified healthcare professionals.

Do not self-inject Trodelvy.

Premedication Before Trodelvy Infusion

Trodelvy can cause infusion-related reactions and nausea or vomiting.

Patients are generally given appropriate premedication before infusion, which may include:

• Antipyretics
• H1 and H2 blockers
• Corticosteroids
• Anti-nausea medicines

The exact premedication regimen is determined by the treating healthcare professional.

Patients are monitored during and after the infusion for signs of hypersensitivity or infusion-related reactions.

Common Side Effects of Trodelvy 200mg

Like all medicines, Trodelvy can cause side effects.

Common adverse effects may include:

• Nausea
• Diarrhea
• Fatigue
• Decreased appetite
• Hair loss
• Constipation
• Vomiting
• Abdominal pain
• Headache
• Cough
• Anemia
• Neutropenia
• Low white blood cell count
• Increased blood glucose
• Reduced albumin levels

The severity and frequency of side effects can vary from patient to patient.

Serious Side Effects of Trodelvy

Severe Neutropenia

Trodelvy can cause significant decreases in neutrophils, which are important white blood cells that help fight infection.

Severe neutropenia may increase the risk of serious infections.

Patients should promptly report:

• Fever
• Chills
• Sore throat
• Persistent cough
• Burning during urination
• Other signs of infection

Blood counts are generally monitored before and during treatment.

Febrile Neutropenia

Neutropenia accompanied by fever can be a medical emergency.

Patients receiving Trodelvy should contact their healthcare team immediately if they develop fever or signs of infection.

Severe Diarrhea

Diarrhea is one of the common adverse effects associated with sacituzumab govitecan and can occasionally become severe.

Persistent or severe diarrhea can result in dehydration and electrolyte abnormalities.

Patients should follow their healthcare team’s instructions for managing diarrhea and report severe or persistent symptoms promptly.

Hypersensitivity and Infusion-Related Reactions

Trodelvy can cause serious hypersensitivity or infusion-related reactions.

Possible symptoms include:

• Rash
• Itching
• Facial swelling
• Difficulty breathing
• Chest discomfort
• Dizziness
• Changes in blood pressure
• Fever or chills

Patients are monitored during administration and appropriate emergency treatment should be available.

Nausea and Vomiting

Nausea is common with Trodelvy and may require preventive or therapeutic antiemetic medicines.

Patients should maintain adequate hydration and follow their healthcare professional’s recommendations.

Trodelvy and UGT1A1 Status

Sacituzumab govitecan releases SN-38, which is metabolized through the UGT1A1 pathway.

Patients with certain UGT1A1 genetic variants, particularly those with reduced UGT1A1 activity, may have an increased risk of neutropenia and other adverse effects.

Healthcare professionals may consider the patient’s clinical history and risk factors when managing treatment.

Precautions Before Using Trodelvy 200mg

Tell your doctor before receiving Trodelvy if you have:

• Low white blood cell counts
• A history of severe neutropenia
• Liver problems
• Previous severe allergic reactions
• Frequent or serious infections
• Persistent diarrhea
• Other serious medical conditions

Tell your healthcare provider about all medicines, supplements and cancer treatments you are currently receiving.

Trodelvy and Drug Interactions

Sacituzumab govitecan releases SN-38, and medicines that affect UGT1A1 activity may potentially alter exposure to the active metabolite.

Your oncologist should review your complete medication list before treatment.

Do not start new medicines or supplements without discussing them with your healthcare provider.

Trodelvy During Pregnancy

Trodelvy may cause fetal harm.

Women who can become pregnant should discuss effective contraception with their healthcare provider before beginning treatment and during the recommended period following the final dose.

Patients who become pregnant while receiving Trodelvy should inform their healthcare professional promptly.

Trodelvy and Breastfeeding

It is not known whether sacituzumab govitecan or its components pass into human breast milk.

Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is generally not recommended during Trodelvy treatment and for the recommended period following treatment.

Discuss breastfeeding with your oncologist before starting therapy.

Trodelvy 200mg Storage

Trodelvy is a specialized biological medicine requiring appropriate storage and handling.

Store the unopened vial according to the manufacturer’s approved storage conditions and protect it from light.

Do not freeze or shake Trodelvy.

Reconstitution and dilution must be performed by trained healthcare professionals using appropriate sterile procedures.

Trodelvy 200mg Injection Price in Pakistan

The Trodelvy 200mg Injection price in Pakistan may vary depending on availability, supplier, import costs, exchange rates and current market conditions.

For the latest Trodelvy 200mg price in Pakistan, customers can contact MedicineWalyDost.com to check current availability and pricing.

As Trodelvy is a specialized oncology medicine, its price may vary significantly depending on supply and market availability. Confirm the latest price before ordering.

Why Choose Trodelvy 200mg Injection?

Trodelvy contains sacituzumab govitecan, an antibody-drug conjugate designed to deliver the potent SN-38 payload to Trop-2-expressing cancer cells.

Its targeted mechanism combines antibody recognition with intracellular delivery of a topoisomerase I inhibitor, providing a specialized treatment approach for selected advanced breast cancer patients.

The product listed here is Trodelvy 200mg Injection, with a pack size of 1 injection/vial.

Treatment should be prescribed and monitored by an experienced oncology team because Trodelvy can cause significant neutropenia, diarrhea, infusion reactions and other potentially serious adverse effects.

Frequently Asked Questions About Trodelvy 200mg

What is Trodelvy 200mg Injection?

Trodelvy 200mg Injection is a prescription antibody-drug conjugate containing sacituzumab govitecan, used in selected patients with advanced or metastatic breast cancer.

What is the generic name of Trodelvy?

The generic name is sacituzumab govitecan.

Who manufactures Trodelvy 200mg?

According to the product information provided, the manufacturer is Zytotoxisch.

What is the pack size of Trodelvy 200mg?

The pack size is 1 injection/vial.

What is Trodelvy used for?

Trodelvy is used in selected patients with unresectable locally advanced or metastatic triple-negative breast cancer and certain patients with HR-positive, HER2-negative advanced or metastatic breast cancer, according to the applicable indication.

How is Trodelvy 200mg administered?

Trodelvy is administered by intravenous infusion by a qualified healthcare professional.

Is 200mg the complete Trodelvy dose?

Not necessarily. The recommended dose is generally calculated according to body weight, so one treatment infusion may require more than one 200mg vial.

What is the usual Trodelvy dose?

The commonly recommended adult dose is 10mg/kg, administered on Days 1 and 8 of a 21-day treatment cycle, unless the treating oncologist prescribes otherwise.

Is Trodelvy chemotherapy?

Trodelvy is an antibody-drug conjugate (ADC). It combines a targeted antibody with a chemotherapy payload called SN-38.

What are the major risks of Trodelvy?

Important risks include severe neutropenia, febrile neutropenia, severe diarrhea, hypersensitivity reactions and infusion-related reactions.

Does Trodelvy cause hair loss?

Yes. Alopecia or hair loss is a commonly reported adverse effect of sacituzumab govitecan.

Can Trodelvy be purchased without a prescription?

Trodelvy is a specialized prescription oncology medicine and should only be used under the supervision of a qualified oncologist.

Order Trodelvy 200mg Injection in Pakistan

Looking for Trodelvy 200mg Injection (Sacituzumab Govitecan) in Pakistan?

MedicineWalyDost.com provides access to specialized prescription medicines and oncology products. Contact us to check the latest Trodelvy 200mg price, availability and ordering information.

Before ordering, confirm the brand, strength, active ingredient, manufacturer, pack size and prescription requirements with your doctor or pharmacist.

Order Trodelvy 200mg Injection from MedicineWalyDost.com and contact us today for current availability and pricing.

Important Medical Disclaimer

Trodelvy 200mg Injection is a prescription oncology medicine. This product description is intended for educational and e-commerce purposes only and does not replace professional medical advice. Sacituzumab govitecan can cause serious or potentially life-threatening adverse effects, including severe neutropenia, febrile neutropenia, diarrhea and infusion-related reactions. Treatment must be prescribed, prepared and administered by qualified healthcare professionals. Do not start, stop or modify treatment without consulting your treating oncologist.